logo
How social media can 'trigger' eating disorders in young people

How social media can 'trigger' eating disorders in young people

Yahoo02-06-2025
Social media can push vulnerable young people towards developing eating disorders by glorifying thinness and promoting fake, dangerous advice about diet and nutrition, experts warn.
Young women and girls are much more likely to suffer from illnesses such as anorexia, bulimia and binge eating disorder, though rates among men have been increasing.
Research has shown the percentage of people worldwide who have had some kind of eating disorder during their lives rose from 3.5 percent in 2000 to 7.8 percent in 2018, a timeframe that captures the rise of social media.
For the professionals trying to help teenagers recover from these disorders, misinformation from influencers on platforms such as TikTok and Instagram is a huge problem.
"We no longer treat an eating disorder without also addressing social media use," French dietitian and nutritionist Carole Copti told AFP.
"It has become a trigger, definitely an accelerator and an obstacle to recovery," she added.
The causes of eating disorders are complex, with psychological, genetic, environmental and social factors all having the potential to make someone more susceptible.
Social media "is not the cause but the straw that may break the camel's back," said Nathalie Godart, a psychiatrist for children and adolescents at the Student Health Foundation of France.
By promoting thinness, strictly controlled diets and relentless exercise, social media weakens already vulnerable people and "amplifies the threat" to their health, she told AFP.
- 'Vicious cycle' -
Just one recent example is the #skinnytok trend, a hashtag on TikTok full of dangerous and guilt-inducing advice encouraging people to drastically reduce how much food they eat.
For Charlyne Buigues, a French nurse specialising in eating disorders, social media serves as a gateway to these problems, which are "normalised" online.
She condemned videos showing young girls with anorexia exposing their malnourished bodies -- or others with bulimia demonstrating their "purges".
"Taking laxatives or vomiting are presented as a perfectly legitimate way to lose weight, when actually they increase the risk of cardiac arrest," Buigues said.
Eating disorders can damage the heart, cause infertility and other health problems, and have been linked to suicidal behaviour.
Anorexia has the highest rate of death of any psychiatric disease, research has found. Eating disorders are also the second leading cause of premature death among 15- to 24-year-olds in France, according to the country's health insurance agency.
Social media creates a "vicious cycle," Copti said.
"People suffering from eating disorders often have low self-esteem. But by exposing their thinness from having anorexia on social media, they gain followers, views, likes... and this will perpetuate their problems and prolong their denial," she added.
This can especially be the case when the content earns money.
Buigues spoke of a young woman who regularly records herself throwing up live on TikTok and who had "explained that she was paid by the platform and uses that money to buy groceries".
- 'Completely indoctrinated' -
Social media also makes recovering from eating disorders "more difficult, more complicated and take longer", Copti said.
This is partly because young people tend to believe the misleading or fake diet advice that proliferates online.
Copti said consultations with her patients can feel like she is facing a trial.
"I have to constantly justify myself and fight to make them understand that no, it is not possible to have a healthy diet eating only 1,000 calories -- that is half what they need -- or that no, it is not normal to skip meals," she said.
"The patients are completely indoctrinated -- and my 45-minute weekly consultation is no match for spending hours every day on TikTok," she added.
Godart warned about the rise of people posing as "pseudo-coaches", sharing incorrect, "absurd" and potentially illegal nutrition advice.
"These influencers carry far more weight than institutions. We're constantly struggling to get simple messages across about nutrition," she said, pointing out that there are lifelines available for those in need.
Buigues takes it upon herself to regularly report problematic content on Instagram, but said it "serves no purpose".
"The content remains online and the accounts are rarely suspended -- it's very tiring," she said.
The nurse has even advised her patients to delete their social media accounts, particularly TikTok.
"It may seem radical but until young people are better informed, the app is too dangerous," she said.
cra-dl/djt
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

Yahoo

time4 minutes ago

  • Yahoo

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay' or the 'Company'), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ('Axis Integrated Mental Health' or 'Axis'), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares. 'Our minority-stake investment in Axis follows our previous investment in Stella, and is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy, while continuing to maintain our core focus on advancing our scientific and technological capabilities to ensure best-in-class support for all our customers. Within this strategy, our investments provide capital injections into high performing healthcare providers, which then allows these businesses to invest in growth drivers and launch new locations,' said Hadar Levy, Chief Executive Officer of BrainsWay. 'We see tremendous opportunities for these healthcare providers to offer expanded services and grow their businesses once they secure the necessary capital.' 'Axis offers a robust clinical services platform and is committed to achieving rapid growth and excellent patient outcomes. We are thrilled to support and collaborate with them as their business continues to scale from a well-respected regional platform to one with a larger footprint, enhancing their delivery of life-changing care to additional patients,' concluded Mr. Levy. 'Our partnership with BrainsWay was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve,' stated Chris Perez, Chief Executive Officer of Axis. 'Given the peerless reputation of BrainsWay and its proprietary Deep TMS technology, we realize the value this strategic partnership will provide as we further advance in our mission of putting patients first through our best-in-class support.' About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit About Axis Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS™ and Spravato®, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof. For more information, please visit Forward-Looking Statement This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's filings with the U.S. Securities and Exchange Commission. Contacts: BrainsWay:Ido MaromChief Financial Investors:Brian RitchieLifeSci Advisors LLCbritchie@ in to access your portfolio

UK Clinicians Want Clearer AI Guidance and Oversight
UK Clinicians Want Clearer AI Guidance and Oversight

Medscape

time6 minutes ago

  • Medscape

UK Clinicians Want Clearer AI Guidance and Oversight

Artificial intelligence (AI) is playing a growing role in healthcare worldwide, but UK clinicians remain cautious, citing practical and ethical concerns, research has revealed. Alongside rising global adoption, regulators are moving to address safety and trust. The Medicines and Healthcare products Regulatory Agency (MHRA) has joined as a founding member of the new Health AI Global Regulatory Network, positioning the UK at the forefront of international oversight. Global Uptake Rising, UK Lags Behind Elsevier's Clinician of the Future 2025 report, published last month, surveyed 2206 clinicians (1781 doctors and 425 nurses) in 109 countries. The responses included answers from 78 UK doctors or physician associates and 31 nurses. Nearly half of respondents globally (48%) reported using AI at work, almost double the 2024 figure of 26%. In the UK, uptake was lower. Only 34% of UK clinicians reported using AI at work, with just 21% of doctors doing so. Common uses included identifying drug interactions (20%), writing clinical notes (18%), second opinions (18%), patient letters (16%), analysing medical images (15%), medication summaries (12%), and multidisciplinary reviews of complex cases (8%). Despite high patient volumes — 60% of UK clinicians said they lacked time to deliver good care, compared with 74% globally — many felt digital diagnostic tools remained inadequate. Scepticism and Distrust UK clinicians were more sceptical than average about AI's potential benefits and were less likely to use it for clinical decision-making, with 53% indicating they would not, and 45% saying they would not rely on AI tools for second opinions. Thirty-three percent described AI as unreliable, compared with 23% who considered it trustworthy. Dr Rahul Goyal, clinical executive at Elsevier and a practising GP, told Medscape News UK that caution reflects the NHS's structure. He cited strict regulatory oversight, national guidelines, evidence-based practice, and accountability as factors. 'While these priorities help safeguard patient care, they can also make clinicians more cautious about adopting new technologies like AI,' he said. He also pointed to 'tech debt' within NHS systems, with many still paper-based and lacking routine clinical decision support. 'As a result, clinicians are understandably more sceptical about using new technologies,' Goyal said. Confidentiality and Trust Most Key When asked what would increase their confidence in AI, 81% of UK clinicians highlighted data confidentiality. The same proportion wanted AI tools trained for factual accuracy, morality, and safety — well above the 63% global average. Trust in international governance was low. Just 27% of UK respondents said they trusted their organisation's AI oversight. Globally, 74% said clearer guidance on AI use would boost trust. The findings align with concerns expressed in Medscape's September 2024 UK Doctors and AI Report. It found that while more than half of clinicians were enthusiastic about the future of AI in healthcare, 1 in 3 of the 745 respondents lacked confidence that it could ensure confidentiality. The vast majority (83%) agreed there was a need for oversight of AI in healthcare settings. Push for Regulation A General Medical Council report earlier this year echoed these concerns, with doctors warning that NHS IT systems must improve before wider adoption. Respondents highlighted concerns about confidentiality risks, over-reliance, de-skilling, errors, and lack of independent evaluation. Many called for regulators to provide more guidance. The lower adoption rate of AI in the UK 'underscores the prevailing caution, and reinforces the need for greater integration, clear guidance, and reassurance as AI becomes more prominent in UK healthcare,' Goyal said. He expressed support for the MHRA's leading role in the new Health AI Global Regulatory Network, describing it as 'a proactive step toward addressing clinicians' concerns.' AI and digital tools are reshaping healthcare, he said, but 'their success depends on building systems that empower clinicians to use them confidently and responsibly.' Looking Ahead While concerns persist, many clinicians see potential benefits. Nearly half (46%) of UK respondents said AI could improve consultation quality, and 62% expected it to improve patient outcomes within 3 years. Goyal said that success depends on integration into NHS systems, clinician training, and patient acceptance. 'If AI is used as a tool to improve access, enhance communication, and empower patients with information, then it is a win,' he said. 'However, if it is poorly implemented or perceived as impersonal, it could widen the gap between GPs and patients.'

UK regulator bans shower gel ad for perpetuating racial stereotypes
UK regulator bans shower gel ad for perpetuating racial stereotypes

CNN

time7 minutes ago

  • CNN

UK regulator bans shower gel ad for perpetuating racial stereotypes

UK Fashion and beauty Race & ethnicityFacebookTweetLink Follow UK regulators have banned a TV commercial for Sanex shower gel after ruling that it 'could be interpreted as suggesting that white skin was superior to black skin.' The Advertising Standards Authority (ASA) acted after receiving complaints about the ad from two people 'who believed the ad perpetuated negative stereotypes about people with darker skin tones,' it said in a statement Wednesday. The spot, which aired in June, featured a Black model whose skin is covered with red scratch marks and another covered with a cracked material that looks like clay. 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24-hour hydration feel,' a voice-over said, accompanying video of a White woman showering. 'Relief could be as simple as a shower,' it added. US consumer products company Colgate-Palmolive, which owns the Sanex brand, said the fact that the ad featured models with different skin tones demonstrated its commitment to diversity, according to the ASA's statement. The regulator said Colgate-Palmolive believed 'the depiction of diverse models in the ad, either experiencing skin discomfort or post-product relief, was utilised in a 'before and after' scenario to show their product was suitable and effective for all, rather than as a comparison based on race or ethnicity.' Clearcast, a company that checks whether TV commercials follow the UK Code of Broadcast Advertising before they can be aired, also said the ad demonstrated the inclusivity of Sanex. While the ASA accepted the argument that the ad showed 'before and after' scenarios to demonstrate the effectiveness of the product, it ruled that its structure was problematic. 'It was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved,' the statement said. 'That could be interpreted as suggesting that white skin was superior to black skin,' it added, while acknowledging that 'we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers.' The ASA added that it had concluded the ad had breached the broadcast advertising code and was likely to cause serious offense. CNN has contacted Colgate-Palmolive for comment.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store